Work

Two Cases of Metastatic Castration‐Resistant Prostate Cancer With Long‐Term Survival Treated With Abiraterone

Year: 2025

Type: article

Abstract: We report two cases of metastatic castration-resistant prostate cancer (mCRPC) with long-term survival following treatment with abiraterone. Despite the generally temporary efficacy of abiraterone, both patients remained progression-free for over 5 years, suggesting that some mCRPC patients may achieve durable responses with abiraterone.

Source: Clinical Case Reports

DOI: 10.1002/ccr3.71617

Authors: Minami Une, Shinya Yamamoto, Honoka Fuse, Ryo Fujiwara, Junji Yonese, Kenjiro Noda

Institutions: The Cancer Institute Hospital, Japanese Foundation For Cancer Research

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,820